Celera Genomics Turnaround Official With Promotion Of Diagnostics Chief
This article was originally published in The Gray Sheet
Executive Summary
The internal selection of Celera Diagnostics President Kathy Ordoñez to succeed Craig Venter as president of Celera Genomics suggests a stronger role for parent Applera Corp. CEO Tony White in the day-to-day operations of the bioinformatics and drug discovery unit
You may also be interested in...
Celera Shifts Focus To Clinical Diagnostics, Deserting Drug Development
Celera Genomics will shed its small-molecule drug development programs to focus on the development of diagnostic tests and discovering proteins useful to pharmaceutical manufacturers
Celera Shifts Focus To Clinical Diagnostics, Deserting Drug Development
Celera Genomics will shed its small-molecule drug development programs to focus on the development of diagnostic tests and discovering proteins useful to pharmaceutical manufacturers
Celera Diagnostics To Develop Genetic Tests For Hospitals And Labs
Celera Diagnostics will develop genetic tests aimed at the $1 bil. molecular diagnostic market, which is currently growing at a 30% clip, as part of a recently launched business strategy to commercialize products based on analysis of the human genome.